AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1329219 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus vincristine plus ifosfamide
Number of subjects: 0
Study 4078182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stimulation colored letters
Number of subjects: 32
Study 4078182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stimulation black letters
Number of subjects: 32
Study 4078182 — intervention group
Group type: COMPARATOR
Intervention: Control group performance
Number of subjects: 32
Study 30488222 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amisulpride
Number of subjects: 318
Study 30488222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 30488222 — intervention group
Group type: COMPARATOR
Intervention: Three-drug control
Number of subjects: 318
Study 30227000 — intervention group
Group type: EXPERIMENTAL
Intervention: Robustness training for high-risk athletes (n = 33)
Number of subjects: 125
Study 30227000 — intervention group
Group type: EXPERIMENTAL
Intervention: Robustness training for low-risk athletes (n = 33)
Number of subjects: 125
Study 30227000 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 125
Study 30227000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (n = 33)
Number of subjects: 125
Study 30227000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (n = 33)
Number of subjects: 125
Study 27870477 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 60 mg
Number of subjects: 27
Study 27870477 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 120 mg
Number of subjects: 27
Study 27870477 — intervention group
Group type: EXPERIMENTAL
Intervention: Noribogaine 180 mg
Number of subjects: 27
Study 27870477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24993856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste (TG+TP)
Number of subjects: 0
Study 24993856 — intervention group
Group type: COMPARATOR
Intervention: Placebo TG+TP
Number of subjects: 0
Study 24993856 — intervention group
Group type: COMPARATOR
Intervention: Placebo TG+marketed 1450 ppmF toothpaste
Number of subjects: 0
Study 24993856 — intervention group
Group type: COMPARATOR
Intervention: Placebo TG+placebo TP
Number of subjects: 0
Study 23215984 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive relationships with mothers or other supportive adults
Number of subjects: 30
Study 20157666 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem with prior enamel acid etching (Etch)
Number of subjects: 31
Study 20157666 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem without prior enamel acid etching (Non-etch)
Number of subjects: 31
Study 17287409 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 34
Study 17287409 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (UTRG)
Number of subjects: 34
Study 17287409 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TRG and UTRG)
Number of subjects: 34
Study 16236891 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase (dornase alfa)
Number of subjects: 25
Study 16236891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12161765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 25, 50 or 100 mg
Number of subjects: 214
Study 12161765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 9883302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (42 mcg per nostril) administered three times daily plus terfenadine 60 mg administered twice daily
Number of subjects: 205
Study 9883302 — intervention group
Group type: COMPARATOR
Intervention: Vehicle nasal spray plus terfenadine 60 mg administered twice daily
Number of subjects: 205
Study 9883302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray plus terfenadine
Number of subjects: 205
Study 9883302 — intervention group
Group type: COMPARATOR
Intervention: Vehicle nasal spray plus terfenadine
Number of subjects: 205
Study 7543494 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I administration
Number of subjects: 14
Study 7543494 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 2087049 — intervention group
Group type: EXPERIMENTAL
Intervention: RBA with adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase, after‐mixing concentration 1:500,000)
Number of subjects: 80
Study 2087049 — intervention group
Group type: COMPARATOR
Intervention: RBA without adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase)
Number of subjects: 80
Study 650879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/ml and Diazepam 0.1 mg/ml administered by intravenous drip at a rate of 0.1 ml/kg/min for the first 5 min and 0.017 ml/kg/min for the next 15 min.
Number of subjects: 30
Study 650879 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.125 mg/kg given intravenously before administration of ketamine-diazepam solution.
Number of subjects: 30
Study 650879 — intervention group
Group type: COMPARATOR
Intervention: Nitrous-oxide and oxygen anesthesia (control group).
Number of subjects: 30
Study 31810829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mobile health-based program with weekly automated assessment and behavior change calls, structured email feedback to caregivers, and fax alerts to clinicians)
Number of subjects: 283
Study 31810829 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 283
Study 31810829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specifically for pulmonary diagnoses)
Number of subjects: 283
Study 31810829 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention group
Number of subjects: 283
Study 30649918 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program
Number of subjects: 0
Study 30649918 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27858951 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy fall reduction home visit program (IG)
Number of subjects: 311
Study 27858951 — intervention group
Group type: COMPARATOR
Intervention: Well-wishing visit from a research assistant (CG)
Number of subjects: 311
Study 25560448 — intervention group
Group type: EXPERIMENTAL
Intervention: WE CARE intervention
Number of subjects: 336
Study 23558806 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week training on cycloergometer, 3 times a week, at 70-80% of max tolerated heart rate (HR) (training group, n = 50)
Number of subjects: 100
Study 23558806 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study 21325226 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic culture (FloraMax, IVS‐Wynco LLC) administered via oral gavage 1 hour post SH challenge.
Number of subjects: 0
Study 21325226 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 19944358 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5mg) plus folic acid (5mg)
Number of subjects: 50
Study 19944358 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus folic acid (5mg)
Number of subjects: 50
Study 19944358 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5mg)
Number of subjects: 50
Study 19944358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19944358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome (death, myocardial infarction, stroke, hospitalization, need for myocardial revascularization)
Number of subjects: 50
Study 19944358 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 50
Study 16765801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cataract surgery on the same day
Number of subjects: 0
Study 16765801 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in 1 eye at a time
Number of subjects: 0
Study 16765801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after surgery
Number of subjects: 0
Study 14970962 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 17
Study 14970962 — intervention group
Group type: COMPARATOR
Intervention: regular therapy
Number of subjects: 17
Study 14970962 — intervention group
Group type: COMPARATOR
Intervention: control (no therapy)
Number of subjects: 17
Study 11779013 — intervention group
Group type: EXPERIMENTAL
Intervention: CT fluoroscopy combined with fluoroscopy (Group A)
Number of subjects: 40
Study 11779013 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy alone (Group B)
Number of subjects: 40
Study 9256515 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct treatment
Number of subjects: 46
Study 9256515 — intervention group
Group type: COMPARATOR
Intervention: Direct observation
Number of subjects: 46
Study 9256515 — intervention group
Group type: COMPARATOR
Intervention: Indirect observation
Number of subjects: 46
Study 8498838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical excision plus radiotherapy (whole brain radiotherapy, 2 fractions per day of 2 Gy for a total of 40 Gy)
Number of subjects: 63
Study 8498838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical excision plus radiotherapy
Number of subjects: 63
Study 8498838 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 63
Study 3481039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 0
Study 3481039 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX-vincristine
Number of subjects: 0
Study 3481039 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug regimens containing HDMTX
Number of subjects: 0
Study 3481039 — intervention group
Group type: COMPARATOR
Intervention: Regimens excluding HDMTX
Number of subjects: 0
Study 30582880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan brush treatment
Number of subjects: 11
Study 30582880 — intervention group
Group type: COMPARATOR
Intervention: Titanium curettes treatment
Number of subjects: 11
Study 30582880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study 29985375 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) based psychotherapy
Number of subjects: 325
Study 29985375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 325
Study 25603363 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Number of subjects: 45
Study 25603363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25231564 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentilla anserina (verum)
Number of subjects: 10
Study 25231564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22385121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% permethrin cream (twice application with a 1-week interval)
Number of subjects: 242
Study 22385121 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin (single dose)
Number of subjects: 242
Study 20123835 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic use of a transparent plastic collector bag
Number of subjects: 25381
Study 20123835 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of postpartum blood loss (control group)
Number of subjects: 25381
Study 18278302 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrofluoric acid application for 2 min plus rinsing and drying, followed by silane application for 30 s (G1)
Number of subjects: 10
Study 18278302 — intervention group
Group type: COMPARATOR
Intervention: Airborne particle abrasion with 30 microm silica oxide particles (CoJet‐Sand) for 20 s, followed by silane application for 5 min (G2)
Number of subjects: 10
Study 16159829 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial conduit (right internal thoracic or radial artery)
Number of subjects: 120
Study 16159829 — intervention group
Group type: COMPARATOR
Intervention: Great saphenous vein graft (control group)
Number of subjects: 120
Study 16159829 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery
Number of subjects: 120
Study 16159829 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 120
Study 16159829 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 120
Study 11837056 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school with peer support (treatment group, n = 47)
Number of subjects: 108
Study 11837056 — intervention group
Group type: COMPARATOR
Intervention: Back school without peer support (control group, n = 46)
Number of subjects: 108
Study 10023644 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin infusion, 100 mL/d for 7 days
Number of subjects: 22
Study 10023644 — intervention group
Group type: COMPARATOR
Intervention: No intervention (disease-control group)
Number of subjects: 22
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoints
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean probing depth
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean probing attachment level
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque index
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoints based on re-entry surgery
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological surrogate endpoints
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple surrogate endpoints
Number of subjects: 82
Study 7601922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss
Number of subjects: 82
Study 2364916 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-inducing horror films
Number of subjects: 12
Study 2364916 — intervention group
Group type: COMPARATOR
Intervention: Romantic family films (control)
Number of subjects: 12
Study 520164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone (i.m. application for induction of early abortion before the 6th week of pregnancy)
Number of subjects: 479
Study 520164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone (i.v. drip for termination of intact and disturbed pregnancies beyond the first trimester)
Number of subjects: 479
Study 520164 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic forms of administration (i.v. and i.m.)
Number of subjects: 479
Study 30973207 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg/day
Number of subjects: 505
Study 30973207 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-GITS 30-60 mg/day
Number of subjects: 505
Study 30973207 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (after missing a dose)
Number of subjects: 505
Study 29121269 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH dose of 100 IU/day
Number of subjects: 521
Study 29121269 — intervention group
Group type: COMPARATOR
Intervention: FSH dose of 150 IU/day
Number of subjects: 521
Study 26508675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin at 50mg/day
Number of subjects: 30
Study 26508675 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride at 1mg/day
Number of subjects: 30
Study 23374559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (daily for 6 months)
Number of subjects: 27
Study 23374559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 6 months)
Number of subjects: 27
Study 23374559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 27
Study 23374559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20093966 — intervention group
Group type: EXPERIMENTAL
Intervention: Postactivation potentiation (PAP) through a 10‐second maximal voluntary contraction (MVC)
Number of subjects: 9
Study 20093966 — intervention group
Group type: COMPARATOR
Intervention: Control (without MVC)
Number of subjects: 9
Study 20093966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic signals during concentric contractions
Number of subjects: 9
Study 19383582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day orally) for 5 days before surgery
Number of subjects: 40
Study 19383582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 40
Study 17223540 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with liquid-based cytology and referral for colposcopy
Number of subjects: 1242
Study 17223540 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 1242
Study 15499270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved diclofenac (Dicloabak)
Number of subjects: 40
Study 15499270 — intervention group
Group type: COMPARATOR
Intervention: Thiomersal-preserved diclofenac
Number of subjects: 40
Study 11484951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and prednisone (M + P)
Number of subjects: 161
Study 11484951 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (P)
Number of subjects: 161
Study 11484951 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA responders (from both groups)
Number of subjects: 161
Study 11484951 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA responders
Number of subjects: 161
Study 9538598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-amylase added to maize-based weaning foods
Number of subjects: 30
Study 9538598 — intervention group
Group type: COMPARATOR
Intervention: Traditionally prepared Amylase-Rich Foods (ARF)
Number of subjects: 30
Study 7846351 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin + navelbine
Number of subjects: 612
Study 7846351 — intervention group
Group type: COMPARATOR
Intervention: cisplatin + vindesine
Number of subjects: 612
Study 7846351 — intervention group
Group type: COMPARATOR
Intervention: navelbine
Number of subjects: 612
Study 3381754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-exercise stress test
Number of subjects: 43
Study 3381754 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 43
Study 31566064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantonese vowel length contrasts perception task (AXB discrimination task)
Number of subjects: 3
Study 31566064 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 English perception
Number of subjects: 3
Study 29888582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (electroacupuncture, acupoint-injection, fire-needle)
Number of subjects: 100
Study 29888582 — intervention group
Group type: COMPARATOR
Intervention: Control (electroacupuncture alone)
Number of subjects: 100
Study 27993811 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy with gemcitabine, dexamethasone, cisplatin (GDP) or dexamethasone, cytarabine, cisplatin (DHAP) followed by autologous stem cell transplantation (ASCT)
Number of subjects: 619
Study 24961994 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 38
Study 24961994 — intervention group
Group type: COMPARATOR
Intervention: Modified Fitness Counts (mFC)
Number of subjects: 38
Study 23422097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subfascial endoscopic perforator surgery (SEPS) and endovenous laser treatment (EVLT)
Number of subjects: 83
Study 23422097 — intervention group
Group type: COMPARATOR
Intervention: Traditional GSV phlebectomy
Number of subjects: 83
Study 20440528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of bovine type II collagen (bCII)
Number of subjects: 0
Study 20440528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of bovine type II collagen (bCII)
Number of subjects: 0
Study 20440528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg of bovine type II collagen (bCII)
Number of subjects: 0
Study 20440528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18328842 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 18328842 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study 17009230 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 17009230 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 17009230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with MTX plus etanercept
Number of subjects: 0
Study 12910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 153
Study 10921554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink) at doses of 0.025-0.6 g/kg
Number of subjects: 42
Study 10921554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink)
Number of subjects: 42
Study 8612381 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) for 7 days
Number of subjects: 12
Study 8612381 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) 2 hours after terfenadine for 7 days
Number of subjects: 12
Study 1473915 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 61
Study 1473915 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 61
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic agent (atropine methonitrate)
Number of subjects: 0
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic agent (salbutamol)
Number of subjects: 0
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both agents
Number of subjects: 0
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic agent first
Number of subjects: 0
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic agent first
Number of subjects: 0